ABBV
AbbVie Inc
AbbVie Inc historical holders
total: 14
Meritage Group AbbVie Inc transactions over time
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Held since:
- 2016 Q4
- Held for:
- 2 quarters
- Latest activity:
- 2017 Q2
Nathaniel Simons has been an institutional investor in AbbVie Inc (ABBV) since 2016 Q4. According to 2026 Q1 report, Nathaniel Simons doesn't hold any shares. The fund/company first acquired ABBV in 2016 Q4, initially purchasing 315,389 shares. Since the initial investment, Meritage Group has made 2 more transactions in this position.
When did Nathaniel Simons exit their ABBV position?
Nathaniel Simons no longer holds AbbVie Inc (ABBV). They sold off their entire position in 2017 Q2, closing out an investment that began in 2016 Q4.
When did Nathaniel Simons first invest in ABBV?
Nathaniel Simons first invested in AbbVie Inc (ABBV) in 2016 Q4 at the reported quarter-end price of $62.62 per share, acquiring 315,389 shares in their initial purchase.
What is Nathaniel Simons's average cost basis for ABBV?
Based on historical transaction data, Nathaniel Simons's estimated cost basis for AbbVie Inc (ABBV) is approximately $63.86 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $63.86
- Weighted AVG sell price:
- $65.16
ABBV transactions history by Meritage Group
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.